ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.407,33
-0,32%
S&P 500
5.354,03
1,18%
US Dollar vs BRL
5,3018
0,00%
Bitcoin
70.919,29
-0,22%
Brent Oil
78,69
0,17%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) Notícias

ARQT Arcutis Biotherapeutics Inc

7,88
0,00 (0,00%)
05 Jun 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Arcutis Biotherapeutics Inc ARQT NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,00 0,00% 7,88 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
7,92 7,83 8,225 7,97 7,88
mais cotações »

Notícias Recentes

Data Hora Fonte Título
05/06/202417:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05/06/202409:00GLOBEArcutis Announces Multiple Abstracts, Including Oral..
03/06/202409:00GLOBEArcutis to Present at the Goldman Sachs 45th Annual Global..
28/05/202408:00PRNCAArcutis Canada annonce l'acceptation aux fins d'examen par..
14/05/202417:00GLOBEArcutis Announces First Quarter 2024 Financial Results and..
14/05/202408:18IHMARKETNEWSUS Futures Remain Steady Amid Wall Street Caution Ahead of..
13/05/202409:00GLOBEExpert Panel Review Further Validates Use of ZORYVE®..
03/05/202417:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
29/04/202417:00GLOBEArcutis to Report First Quarter 2024 Financial Results..
10/04/202409:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05/04/202417:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/04/202408:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/03/202409:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/03/202409:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10/03/202417:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09/03/202418:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
05/03/202418:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04/03/202418:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04/03/202410:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
29/02/202419:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/02/202401:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28/02/202418:10GLOBEArcutis Announces Proposed Public Offering
28/02/202418:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27/02/202407:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
16/02/202410:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
06/02/202418:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
31/01/202410:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
29/01/202410:00GLOBEJournal of the American Academy of Dermatology Publishes..
22/01/202410:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
14/01/202406:00GLOBEZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic..
15/12/202320:13DJNArcutis Biotherapeutics Shares Jump After FDA OKs..
15/12/202319:49DJNArcutis Biotherapeutics' Application for Seborrheic..
15/12/202319:11GLOBEFDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam,..
02/12/202300:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
29/11/202310:00GLOBEFDA Accepts Arcutis’ Supplemental New Drug Application for..
03/11/202308:30GLOBEArcutis Announces Third Quarter 2023 Financial Results and..
02/11/202317:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
25/10/202317:00GLOBEArcutis to Report Third Quarter 2023 Financial Results
20/10/202309:00GLOBENew Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided..
20/10/202300:45GLOBEArcutis Announces Pricing of $100 Million Public Offering
19/10/202317:04GLOBEArcutis Announces Proposed Public Offering
13/10/202309:00GLOBEArcutis Presents Positive Patient-Reported Outcome Data from..
06/10/202309:52DJNArcutis Biotherapeutics Shares Rise Premarket As FDA OKs..
06/10/202309:00GLOBEFDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for..
05/10/202317:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
27/09/202309:00GLOBEArcutis Appoints L. Todd Edwards as Chief Commercial Officer
25/09/202310:00GLOBENew Campaign from Arcutis Aims to Educate, Raise Awareness,..
19/09/202308:30GLOBEArcutis Announces Positive Results from INTEGUMENT-PED..
15/09/202317:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
12/09/202308:30GLOBEArcutis Submits Roflumilast Cream 0.15% Supplemental New..

Seu Histórico Recente

NASDAQ
ARQT
Arcutis Biotherapeutics
BIT
SCOP
ETFS 1x Daily Short Copper
BIT
I07581
INTESA SANPAOLO
BIT
HPSDYN
Hypo Portfolio Selection...
NASDAQ
SFBS
ServisFirst Bancshares
BIT
W68AR9
UBS
DBI
D1ER
WKN A30A2S
BIT
S27875
Societe Generale Effekten
COIN
LHBUST
Lendhub
COIN
OVRETH
OVR
BIT
P1YKD4
NLBNPIT1YKD4 20351219 16...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados